To establish TriKE specific activity against HER2 expressing cells, NK cell activation was measured by evaluation of NK cell degranulation (CD107a) and inflammatory cytokine production (IFNγ) when PBMCs were incubated with tumor HER2+/− targets and the CAM1615HER2 TriKE or controls. The gene discussed is LAMP1; the disease is neoplasm.